Summary
Biogen reported positive 18 months data for Alzheimer’s treatment BAN2401.
The results report left out some key data and explanation for changed methodology.
The stock looks overpriced following recent steep rise.
Our opinion may change after the AAIC data, but right now, we are avoiding BIIB.
This idea was discussed in more depth with members of my private investing community, The Total Pharma Tracker.
Biogen Inc. (BIIB) stock reversed its Year to Date performance as it shot up in the market in recent days. The stock reacted to the company’s announcement about its potential Alzheimer’s treatment.
Biogen came out with positive news about its lead drug candidate BAN2401, an amyloid antibody, which was more or less completely written off by the market following its Phase II debacle nearly a year back, when it flunked a Bayesian analysis at 12 months. That write-off was indicated by shares of BIIB falling 4% in the day following the announcement. That study failed to meet its primary endpoint after BAN2401 failed to show an 80 percent or higher probability of achieving a Clinically Significant Difference based on the Bayesian analysis.
READ FULL ARTICLE

